CERS


Cerus: Ebola Outbreak Lowers FDA Risk Further, Says Wedbush

In a research report published today, Wedbush analyst Zarak Khurshid maintained coverage on Cerus Corp. (NASDAQ:CERS) with an Outperform rating and a $6.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts